Andy Chi

Practical considerations of utilizing propensity score methods in clinical development utilizing real-world and historical data.

Sheryl M. Davies, Jianchang Lin, Qing Li, 2020, Contemporary clinical trials.

Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas.

S. Pileri, P. Zinzani, D. Huebner, 2016, Critical reviews in oncology/hematology.

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

A. Nademanee, P. Stiff, V. Bachanova, 2015, The Lancet.

Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Cutaneous T-cell lymphomas.

S. Pileri, P. Zinzani, D. Huebner, 2016, Critical reviews in oncology/hematology.

Brentuximab vedotin compared with other therapies in relapsed/refractory Hodgkin lymphoma post autologous stem cell transplant: median overall survival meta-analysis

A. Gautam, E. Wu, R. Ayyagari, 2015, Current medical research and opinion.

Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data

E. Wu, A. Macalalad, D. Huebner, 2015, Current medical research and opinion.

External Control Using RWE and Historical Data in Clinical Development

Sheryl M. Davies, Guang-sheng Chen, Jianchang Lin, 2021 .